Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 774

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 774
---
 (“Amendment No. 2”). Amendment No. 2 amends the Merger Agreement to, among other things, modify the definitions of the “Exchange Ratio” and “Merger Consideration” to facilitate the issuance of additional shares of common stock of Semnur prior to the closing of the Business Combination in connection with any potential private placement financing or for issuance to advisors and other service providers for services rendered and maintain the 1.25-to-1 exchange ratio. On August 11, 2025, Scilex deposited an additional $ 874.78, drawn down from the Extension Scilex Convertible Promissory Note, to the Trust Account to extend the time the Company has to consummate an initial business combination to September 11, 2025. F-34

DENALI CAPITAL ACQUISITION CORP. CONDENSED CONSOLIDATED BALANCE SHEETS

| Assets                                                                                                                                                                                                                                                        |     | March 31,2025 
 (Unaudited)   |             |   |     | December 31,2024 |             |   |
|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:--------------|------------:|:--|:----|:-----------------|------------:|:--|
| Cash on hand                                                                                                                                                                                                                                                  |     | $             |       2,736 |   |     | $                |      16,868 |   |
| Total current assets                                                                                                                                                                                                                                          |     |               |       2,736 |   |     |                  |      16,868 |   |
| Cash and Investments held in trust                                                                                                                                                                                                                            |     |               |   9,145,167 |   |     |                  |   9,021,005 |   |
| Total assets                                                                                                                                                                                                                                                  |     | $             |   9,147,903 |   |     | $                |   9,037,873 |   |
| Liabilities and Shareholders’ Deficit                                                                                                                                                                                                                         |     |               |             |   |     |                  |             |   |
| Accounts Payable and accrued offering costs and expenses                                                                                                                                                                                                      |     | $             |   4,772,883 |   |     | $                |   4,640,414 |   |
| Accrued interest expense - related party                                                                                                                                                                                                                      |     |               |      91,764 |   |     |                  |      74,555 |   |
| Accrued